Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q3 Net Loss Lowered on Valuation of Acquired Tm Assets

NEW YORK (GenomeWeb News) – Luminex said Friday that it has completed a preliminary valuation of acquired intangible assets related to its March acquisition of Tm Bioscience, which has since been renamed Luminex Molecular Diagnostics.
 
As a result of the updated valuation, Luminex lowered its third-quarter net loss to $1.9 million from the previously reported $3.3 million.
 
Luminex has recorded $30.8 million of goodwill related to the acquisition and has increased the goodwill balance to $39.6 million with $26.2 million being allocated to “identified acquired intangible assets.” Of that $26.2 million, $7.4 million represents in-process research and development, said Luminex.
 
Overall, the modifications consist of $8.8 million being allocated from intangible assets to goodwill, and $1.1 million being allocated from in-process research and development to goodwill. Luminex said these changes enabled it to recapture $600,000 during the three-month period ended Sept. 30.
 
The intangible assets will contribute $566,000 in amortization expense to each of the next three quarters and then decrease to roughly $500,000 per quarter for an unspecified period thereafter.
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.